PE20221515A1 - Oxinitruro de piridina, metodo para su preparacion y uso de este - Google Patents

Oxinitruro de piridina, metodo para su preparacion y uso de este

Info

Publication number
PE20221515A1
PE20221515A1 PE2022000407A PE2022000407A PE20221515A1 PE 20221515 A1 PE20221515 A1 PE 20221515A1 PE 2022000407 A PE2022000407 A PE 2022000407A PE 2022000407 A PE2022000407 A PE 2022000407A PE 20221515 A1 PE20221515 A1 PE 20221515A1
Authority
PE
Peru
Prior art keywords
oxinitride
pyridine
preparation
refers
compounds
Prior art date
Application number
PE2022000407A
Other languages
English (en)
Inventor
Qiong Zhang
Zhongli Wang
Ming Dai
Fengkai Cheng
Jiu Luo
Yan Ye
Jianbiao Peng
Haibing Guo
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of PE20221515A1 publication Critical patent/PE20221515A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXINITRURO DE PIRIDINA DE FORMULA (I) DONDE R1, R2, R3, R4, R5, R6, R13, T1, T2, T3, T4, L1, L2 Y n SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS LOS DE FORMULAS (A5), (A22), (A33), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS PRESENTAN ACTIVIDAD BLOQUEANTE DE LOS CANALES DE SODIO 1.8 (NaV1.8) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR.
PE2022000407A 2019-09-12 2020-09-11 Oxinitruro de piridina, metodo para su preparacion y uso de este PE20221515A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910863718 2019-09-12
CN201911094782 2019-11-11
CN202010531381 2020-06-11
CN202010923311 2020-09-04
PCT/CN2020/114700 WO2021047622A1 (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
PE20221515A1 true PE20221515A1 (es) 2022-10-04

Family

ID=74866555

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000407A PE20221515A1 (es) 2019-09-12 2020-09-11 Oxinitruro de piridina, metodo para su preparacion y uso de este

Country Status (15)

Country Link
US (1) US20230303495A9 (es)
EP (1) EP4043437A4 (es)
JP (1) JP2022548104A (es)
KR (1) KR20220101606A (es)
CN (2) CN112479996B (es)
AU (1) AU2020346951A1 (es)
BR (1) BR112022004495A8 (es)
CA (1) CA3150400A1 (es)
CL (1) CL2022000619A1 (es)
CO (1) CO2022004594A2 (es)
MX (1) MX2022003032A (es)
PE (1) PE20221515A1 (es)
TW (1) TWI770607B (es)
WO (1) WO2021047622A1 (es)
ZA (1) ZA202204100B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300147A (zh) * 2021-03-11 2023-01-01 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物晶型及其應用
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
UY39800A (es) 2021-06-04 2023-01-31 Vertex Pharma N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
EP4347032A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023186102A1 (zh) * 2022-04-02 2023-10-05 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023232117A1 (zh) * 2022-06-02 2023-12-07 上海济煜医药科技有限公司 吡啶氮氧化合物的制备方法
WO2023246867A1 (zh) * 2022-06-22 2023-12-28 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
JP5149003B2 (ja) * 2005-06-21 2013-02-20 三井化学アグロ株式会社 アミド誘導体ならびに該化合物を含有する殺虫剤
CA2648202A1 (en) * 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2010047480A (ja) * 2006-12-19 2010-03-04 Mitsui Chemicals Inc 虫害の予防方法
US8389734B2 (en) * 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
EP2212290B1 (en) * 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP2014500303A (ja) * 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
AR094668A1 (es) * 2013-01-31 2015-08-19 Vertex Pharma Amidas como moduladores de canales de sodio
ES2620379T3 (es) * 2013-01-31 2017-06-28 Vertex Pharmaceuticals Inc. Quinolina y quinoxalina amidas como moduladores de canales de sodio
PT3239134T (pt) * 2013-01-31 2021-01-28 Vertex Pharma Piridona amidas como moduladores dos canais de sódio
GEP20217223B (en) * 2013-12-13 2021-02-10 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
TW201920081A (zh) * 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
EP3820866A4 (en) * 2018-07-09 2022-04-06 Lieber Institute, Inc. PYRIDINE CARBOXAMIDE COMPOUNDS TO INHIBIT NAV1.8

Also Published As

Publication number Publication date
TW202114990A (zh) 2021-04-16
KR20220101606A (ko) 2022-07-19
CN112479996B (zh) 2023-05-26
EP4043437A1 (en) 2022-08-17
EP4043437A4 (en) 2023-10-04
CA3150400A1 (en) 2021-03-18
AU2020346951A1 (en) 2022-04-28
US20230026907A1 (en) 2023-01-26
JP2022548104A (ja) 2022-11-16
BR112022004495A2 (pt) 2022-05-31
TWI770607B (zh) 2022-07-11
WO2021047622A1 (zh) 2021-03-18
CN113906013B (zh) 2024-03-12
CL2022000619A1 (es) 2022-10-28
CN112479996A (zh) 2021-03-12
US20230303495A9 (en) 2023-09-28
ZA202204100B (en) 2024-04-24
CO2022004594A2 (es) 2022-07-08
CN113906013A (zh) 2022-01-07
BR112022004495A8 (pt) 2023-04-18
MX2022003032A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
PE20221515A1 (es) Oxinitruro de piridina, metodo para su preparacion y uso de este
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
UY38979A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
PE20181352A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
BR112022003982A2 (pt) Compostos heterocíclicos
CL2020000553A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
CO2023000056A2 (es) Derivados de amidopirimidona
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CL2022000628A1 (es) Compuestos de amina cíclica activos como plaguicidas.
UY38816A (es) Nuevos derivados de isoquinolina
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
AR040456A1 (es) Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo